##gff-version 3
##sequence-region P03950 1 147
P03950	UniProtKB	Signal peptide	1	24	.	.	.	Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:2866794;Dbxref=PMID:2866794	
P03950	UniProtKB	Chain	25	147	.	.	.	ID=PRO_0000030843;Note=Angiogenin;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:2866794,ECO:0000269|PubMed:2866795;Dbxref=PMID:2866794,PMID:2866795	
P03950	UniProtKB	Region	64	68	.	.	.	Note=Substrate binding	
P03950	UniProtKB	Motif	55	59	.	.	.	Note=Nucleolar localization signal	
P03950	UniProtKB	Active site	37	37	.	.	.	Note=Proton acceptor	
P03950	UniProtKB	Active site	138	138	.	.	.	Note=Proton donor	
P03950	UniProtKB	Modified residue	25	25	.	.	.	Note=Pyrrolidone carboxylic acid;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:2866794;Dbxref=PMID:2866794	
P03950	UniProtKB	Disulfide bond	50	105	.	.	.	Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:2866794;Dbxref=PMID:2866794	
P03950	UniProtKB	Disulfide bond	63	116	.	.	.	Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:2866794;Dbxref=PMID:2866794	
P03950	UniProtKB	Disulfide bond	81	131	.	.	.	Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:2866794;Dbxref=PMID:2866794	
P03950	UniProtKB	Natural variant	12	12	.	.	.	ID=VAR_044145;Note=In ALS9. F->S;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:18087731;Dbxref=PMID:18087731	
P03950	UniProtKB	Natural variant	20	20	.	.	.	ID=VAR_044146;Note=In ALS9. P->S;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:17886298,ECO:0000269|PubMed:18087731;Dbxref=PMID:17886298,PMID:18087731	
P03950	UniProtKB	Natural variant	36	36	.	.	.	ID=VAR_044147;Note=In ALS9%3B reduced ribonucleolytic activity%3B low angiogenic activity%3B reduced mitogenic activity%3B wild type far-UV CD spectra. Q->L;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:16501576,ECO:0000269|PubMed:17900154;Dbxref=dbSNP:rs121909535,PMID:16501576,PMID:17900154	
P03950	UniProtKB	Natural variant	38	38	.	.	.	ID=VAR_073021;Note=In ALS9. Y->H;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:22292843;Dbxref=dbSNP:rs1032422334,PMID:22292843	
P03950	UniProtKB	Natural variant	41	41	.	.	.	ID=VAR_044148;Note=In ALS9%3B reduced ribonucleolytic activity. K->E;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:16501576,ECO:0000269|PubMed:17900154;Dbxref=dbSNP:rs121909537,PMID:16501576,PMID:17900154	
P03950	UniProtKB	Natural variant	41	41	.	.	.	ID=VAR_044149;Note=In ALS9%3B loss of angiogenic activity%3B reduced ribonucleolytic activity%3B retains nuclear translocation. K->I;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:16501576,ECO:0000269|PubMed:17886298,ECO:0000269|PubMed:17900154,ECO:0000269|PubMed:22292843;Dbxref=dbSNP:rs121909536,PMID:16501576,PMID:17886298,PMID:17900154,PMID:22292843	
P03950	UniProtKB	Natural variant	46	46	.	.	.	ID=VAR_073022;Note=In ALS9%3B homodimerization is similar to wild-type%3B localization in the nucleus is similar to the wild-type%3B reduces strongly ribonucleolytic activity. D->G;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:22292843,ECO:0000269|PubMed:25372031;Dbxref=dbSNP:rs1440927797,PMID:22292843,PMID:25372031	
P03950	UniProtKB	Natural variant	52	52	.	.	.	ID=VAR_044150;Note=In ALS9%3B loss of angiogenic activity%3B reduced ribonucleolytic activity%3B unable to translocate to the nucleus. S->N;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:17886298;Dbxref=dbSNP:rs121909542,PMID:17886298	
P03950	UniProtKB	Natural variant	55	55	.	.	.	ID=VAR_044151;Note=In ALS9%3B marginally reduced ribonucleolytic activity%3B wild type far-UV CD spectra. R->K;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:16501576,ECO:0000269|PubMed:17900154;Dbxref=dbSNP:rs121909538,PMID:16501576,PMID:17900154	
P03950	UniProtKB	Natural variant	63	63	.	.	.	ID=VAR_044152;Note=In ALS9%3B reduced ribonucleolytic activity%3B low angiogenic activity%3B reduced mitogenic activity%3B reduced thermal stability. C->W;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:16501576,ECO:0000269|PubMed:17900154;Dbxref=dbSNP:rs121909539,PMID:16501576,PMID:17900154	
P03950	UniProtKB	Natural variant	64	64	.	.	.	ID=VAR_044153;Note=In ALS9%3B reduced ribonucleolytic activity%3B low angiogenic activity%3B reduced mitogenic activity%3B moderate reduction of thermal stability. K->I;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:15557516,ECO:0000269|PubMed:16501576,ECO:0000269|PubMed:17900154;Dbxref=dbSNP:rs121909540,PMID:15557516,PMID:16501576,PMID:17900154	
P03950	UniProtKB	Natural variant	70	70	.	.	.	ID=VAR_044154;Note=In some ALS9 patients%3B pathogenicity uncertain%3B reduced ribonucleolytic activity%3B moderate reduction of thermal stability. I->V;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:16501576,ECO:0000269|PubMed:17900154,ECO:0000269|PubMed:18087731;Dbxref=dbSNP:rs121909541,PMID:16501576,PMID:17900154,PMID:18087731	
P03950	UniProtKB	Natural variant	84	84	.	.	.	ID=VAR_013148;Note=K->E;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:11919285;Dbxref=dbSNP:rs17560,PMID:11919285	
P03950	UniProtKB	Natural variant	136	136	.	.	.	ID=VAR_044155;Note=In ALS9%3B loss of angiogenic activity%3B reduced ribonucleolytic activity%3B unable to translocate to the nucleus. P->L;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:17886298;Dbxref=dbSNP:rs121909543,PMID:17886298	
P03950	UniProtKB	Natural variant	137	137	.	.	.	ID=VAR_044156;Note=In ALS9. V->I;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:18087731;Dbxref=dbSNP:rs121909544,PMID:18087731	
P03950	UniProtKB	Natural variant	138	138	.	.	.	ID=VAR_044157;Note=In ALS9. H->R;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:18087731;Dbxref=PMID:18087731	
P03950	UniProtKB	Mutagenesis	29	29	.	.	.	Note=Significantly decreases binding affinity for RNH1. R->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:10413501;Dbxref=PMID:10413501	
P03950	UniProtKB	Mutagenesis	32	32	.	.	.	Note=Significantly decreases binding affinity for RNH1. H->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:9050852;Dbxref=PMID:9050852	
P03950	UniProtKB	Mutagenesis	36	36	.	.	.	Note=Slightly decreases binding affinity for RNH1. Q->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:9050852;Dbxref=PMID:9050852	
P03950	UniProtKB	Mutagenesis	59	59	.	.	.	Note=Homodimerization is similar to wild-type%3B causes mislocalization in the cytoplasm%3B reduces strongly ribonucleolytic activity. L->P;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:25372031;Dbxref=PMID:25372031	
P03950	UniProtKB	Mutagenesis	64	64	.	.	.	Note=Significantly decreases binding affinity for RNH1. K->Q;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:10413501,ECO:0000269|PubMed:9050852;Dbxref=PMID:10413501,PMID:9050852	
P03950	UniProtKB	Mutagenesis	92	92	.	.	.	Note=Slightly decreases binding affinity for RNH1. N->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:9050852;Dbxref=PMID:9050852	
P03950	UniProtKB	Mutagenesis	109	110	.	.	.	Note=Significantly decreases binding affinity for RNH1. GG->RR;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:19354288;Dbxref=PMID:19354288	
P03950	UniProtKB	Mutagenesis	132	132	.	.	.	Note=Slightly decreases binding affinity for RNH1. E->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:9050852;Dbxref=PMID:9050852	
P03950	UniProtKB	Mutagenesis	140	140	.	.	.	Note=15- to 18-fold increase in RNase activity. D->H%2CS%2CA;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:11851402;Dbxref=PMID:11851402	
P03950	UniProtKB	Mutagenesis	141	141	.	.	.	Note=Over 18-fold increase in RNase activity. Q->G;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:11851402;Dbxref=PMID:11851402	
P03950	UniProtKB	Mutagenesis	143	144	.	.	.	Note=3- to 5-fold increase in RNase activity. IF->AA;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:11851402;Dbxref=PMID:11851402	
P03950	UniProtKB	Sequence conflict	59	59	.	.	.	Note=L->P;Ontology_term=ECO:0000305;evidence=ECO:0000305	
P03950	UniProtKB	Turn	19	21	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:4B36	
P03950	UniProtKB	Beta strand	22	24	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:4B36	
P03950	UniProtKB	Helix	28	37	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:4AOH	
P03950	UniProtKB	Helix	47	56	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:4AOH	
P03950	UniProtKB	Turn	60	63	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:4AOH	
P03950	UniProtKB	Beta strand	65	70	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:4AOH	
P03950	UniProtKB	Helix	74	78	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:4AOH	
P03950	UniProtKB	Helix	79	81	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:4AOH	
P03950	UniProtKB	Turn	83	85	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:4AOH	
P03950	UniProtKB	Beta strand	86	89	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:4AOH	
P03950	UniProtKB	Turn	90	92	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:4AOH	
P03950	UniProtKB	Beta strand	93	98	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:4AOH	
P03950	UniProtKB	Beta strand	100	110	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:4AOH	
P03950	UniProtKB	Beta strand	112	115	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:4AOH	
P03950	UniProtKB	Beta strand	117	125	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:4AOH	
P03950	UniProtKB	Beta strand	128	132	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:4AOH	
P03950	UniProtKB	Beta strand	135	139	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:4AOH	
P03950	UniProtKB	Helix	141	144	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:4AOH	
